Find out what’s happening at MSWA, from our range of activities and programs to corporate news.
Also, read about the latest developments in neurological research, scientific discoveries, new medications and treatments in the areas of neurological conditions.
Ofatumumab (Kesimpta®) approved by The Therapeutic Goods Administration (TGA) of Australia as a new treatment for relapsing forms of MS.
MSWA is proud to be Western Australia’s leading contributor to neurological research. This year, we are delighted to announce a new record contribution of $4m.
MSWA is taking precautionary measures to protect the health and wellbeing of our community during the COVID-19 (coronavirus) outbreak.